Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Rackspace jumped after partnering with AMD to build secure AI cloud for banks and hospitals using AMD + Nvidia chips for AI workloads.
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
ARM beat earnings and saw strong demand for AI chips, but shares fell on smartphone worries amid supply concerns. Analysts still raised price targets.
Peloton Q3 shows profit, higher revenue, strong cash flow, less debt, but subscribers still falling; outlook improved.
Datadog beat earnings and revenue, raised outlook, and stock jumped 29% as AI demand boosts its cloud monitoring business.